Роль генетического полиморфизма PAI-1 4G/5G в развитии коронарной болезни сердца.

I.M. Lee, H.D. Sesso, Y. Oguma, R.S. Paffenbarger Jr., Relative Intensity of Physical Activity and Risk of Coronary Heart Disease, Circulation, 2003, 107, 1110–1116, 10.1161/01.cir.0000052626.63602.58.

S.H. Wild, C.D. Byrne, ABC of Obesity. Risk Factors for Diabetes and Coronary Heart Disease, BMJ, 2006, 333, 1009–1011, 10.1136/bmj.39024.568738.43.

J. Hsu, J.D. Smith, Genomic Expression Studies of Genes Related to Coronary Heart Disease, Current Opinion in Cardiology, 2012, 27, 210–213, 10.1097/HCO.0b013e3283522198.

D.E. Vaughan, PAI-1 and Atherothrombosis, Journal of Thrombosis and Haemostasis, 2005, 3, 1879–1883, 10.1111/j.1538-7836.2005.01420.x.

R. Renckens, J.J. Roelofs, V. de Waard, S. Florquin, H.R. Lijnen, P. Carmeliet, T. van der Poll, The Role of Plasminogen Activator Inhibitor Type 1 in the Inflammatory Response to Local Tissue Injury, Journal of Thrombosis and Haemostasis, 2005, 3, 1018–1025, 10.1111/j.1538-7836.2005.01311.x.

S. Dawson, A. Hamsten, B. Wiman, A. Henney, S. Humphries, Genetic variability at the plasminogen activator inhibitor-1 locus is associated with altered plasma plasminogen activator inhibitor-1 activity levels, Arteriosclerosis and Thrombosis, 1991, 11, 183–190, 10.1161/01.atv.11.1.183.

P. Eriksson, B. Kallin, F.M. van’t Hooft, P. Ba˚venholm, A. Hamsten, Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction, Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1851–1855, 10.1073/pnas.92.6.1851.

J. Schneiderman, M.S. Sawdey, M.R. Keeton, G.M. Bordin, E.F. Bernstein, R.B. Dilley, D.J. Loskutoff, Increased Type 1 Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries, Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6998–7002, 10.1073/pnas.89.15.6998.

P.N. Raghunath, J.E. Tomaszewski, S.T. Brady, R.J. Caron, S.S. Okada, E.S. Barnathan, The plasminogen activator system in atherosclerosis of human coronary arteries, Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1432–1443, 10.1161/01.atv.15.9.1432.

F. Lupu, G.E. Bergonzelli, D.A. Heim, E. Cousin, C.Y. Genton, F. Bachmann, E.K. Kruithof, Localization and production of plasminogen activator inhibitor-1 in healthy and atherosclerotic human arteries, Arteriosclerosis and Thrombosis, 1993, 13, 1090–1100, 10.1161/01.atv.13.7.1090.

B.E. Sobel, J. Woodcock-Mitchell, D.J. Schneider, R.E. Holt, K. Marutsuka, H. Gold, Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence, Circulation, 1998, 97, 2213–2221, 10.1161/01.cir.97.22.2213.

G.H. Tofler, J. Massaro, C.J. O’Donnell, P.W. F. Wilson, R.S. Vasan, P.A. Sutherland, J.B. Meigs, D. Levy, R.B. D’Agostino Sr., Plasminogen Activator Inhibitor and the Risk of Cardiovascular Disease: The Framingham Heart Study, Thrombosis Research, 2016, 140, 30–35, 10.1016/j.thromres.2016.02.002.

Karin Leander, Bjorn Wiman, Johan Hallqvist, Margareta Sten-Linder, Ulf de Faire, PAI-1 Level and the PAI-1 4G/5G Polymorphism in Relation to Risk of Non-Fatal Myocardial Infarction, Thrombosis and Haemostasis, 2003, 89, 1064–1071, 10.1055/s-0037-1613409.

Zhongshu Liang, Weihong Jiang, Mao Ouyang, Kan Yang, PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis, International Journal of Clinical and Experimental Medicine, 2015, 8, 02, 2097–2107.

S. Ye, F.R. Green, P.Y. Scarabin, V. Nicaud, L. Bara, S.J. Dawson, The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study, Thrombosis and Haemostasis, 1995, 74, 837–841.

M.W. Mansfield, M.H. Stickland, P.J. Grant, Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes, Thrombosis and Haemostasis, 1995, 74, 1032–1034.

F. Burzotta, A. Di Castelnuovo, C. Amore, A. D’Orazio, M.B. Donati, L. Iacoviello, 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years, Thrombosis and Haemostasis, 1997, 78, 1294–1295.

P.M. Ridker, C.H. Hennekens, K. Lindpaintner, M.J. Stampfer, J.P. Miletich, Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men, Circulation, 1997, 95, 59–62, 10.1161/01.cir.95.1.59.

Machteld Sillen, Paul J. Declerck, Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition, Frontiers in Cardiovascular Medicine, 2020, 7, 10.3389/fcvm.2020.622473, Published: 22 December 2020, Section: Atherosclerosis and Vascular Medicine.

Irma Isordia-Salas, Alfredo Lean˜os-Miranda, Irma M. Sainz, Elba Reyes-Maldonado, Gabriela Borrayo-Sa´nchez, Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients, Revista Espan˜ola de Cardiolog´ıa, 2009, 62, 04, 365–372, 10.1016/s1885-5857(09)71663-9.